Wanbury Limited has announced the launch of new API (Active Pharmaceutical Ingredient) products as part of its growing product portfolio. According to the company’s recent exchange filing, the newly launched APIs include Metformin HCl, Sertraline HCl, and Diphenhydramine Citrate, among others, covering a wide range of therapeutic areas like anti-diabetic, anti-depressant, and analgesics.
In addition to its current offerings, Wanbury has plans to launch more APIs in FY24-25, such as Dextromethorphan HBr and Ketamine HCl, which are aimed at antitussive and anesthetic markets. These launches will strengthen Wanbury’s presence in both domestic and international markets, as the company continues to expand its pipeline with high-demand products.
This marks an important step for Wanbury in catering to the growing global demand for quality APIs, while enhancing its competitive edge in the pharmaceutical industry.
